These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
672 related articles for article (PubMed ID: 18282788)
21. [Bisphosphonate-associated osteonecrosis of the jaw]. Abu-Id MH; Açil Y; Gottschalk J; Kreusch T Mund Kiefer Gesichtschir; 2006 Mar; 10(2):73-81. PubMed ID: 16456688 [TBL] [Abstract][Full Text] [Related]
22. [Bisphosphonates and osteonecrosis of the jaws]. Urade M Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882 [TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. Favia G; Pilolli GP; Maiorano E J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275 [TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482 [TBL] [Abstract][Full Text] [Related]
25. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Van Poznak C; Estilo C Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349 [TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622 [TBL] [Abstract][Full Text] [Related]
27. Osteonecrosis of the jaw associated with pamidronate therapy. Zarychanski R; Elphee E; Walton P; Johnston J Am J Hematol; 2006 Jan; 81(1):73-5. PubMed ID: 16369966 [TBL] [Abstract][Full Text] [Related]
28. Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Ferlito S; Liardo C; Puzzo S Minerva Stomatol; 2010; 59(11-12):593-601. PubMed ID: 21217623 [TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657 [TBL] [Abstract][Full Text] [Related]
30. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review]. Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077 [TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978 [TBL] [Abstract][Full Text] [Related]
32. Osteonecrosis of the jaw: who gets it, and why? Reid IR Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230 [TBL] [Abstract][Full Text] [Related]
33. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574 [TBL] [Abstract][Full Text] [Related]
34. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404 [TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Badros A; Weikel D; Salama A; Goloubeva O; Schneider A; Rapoport A; Fenton R; Gahres N; Sausville E; Ord R; Meiller T J Clin Oncol; 2006 Feb; 24(6):945-52. PubMed ID: 16484704 [TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Brooks JK; Gilson AJ; Sindler AJ; Ashman SG; Schwartz KG; Nikitakis NG Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):780-6. PubMed ID: 17223592 [TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158 [TBL] [Abstract][Full Text] [Related]
38. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865 [TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147 [TBL] [Abstract][Full Text] [Related]